FDG has also been proposed as a marker of other conditions of interest in clinical dementia populations beyond those associated with Alzheimer’s disease-tau, such as hippocampal sclerosis and TDP-43,74 DLB54,75,76 and is currently approved and covered by Medicare for clinical use in the differential diagnosis of FTD and Alzheimer’s disease. This evidence concerns the gene MAPT and dementia.